Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia by Thai Hoa Tran, Marian H. Harris, Jonathan V. Nguyen, Traci M. Blonquist, Kristen E. Stevenson, Eileen Stonerock, Barbara L. Asselin, Uma H. Athale, Luis A. Clavell, Peter D. Cole, Kara M. Kelly, Caroline Laverdiere, Jean-Marie Leclerc, Bruno Michon, Marshall A. Schorin, Jennifer J. G. Welch, Shalini C. Reshmi, Donna S. Neuberg, Stephen E. Sallan, Mignon L. Loh, and Lewis B. Silverman BloodAdv Volume 2(5):529-533 March 13, 2018 © 2018 by The American Society of Hematology

Thai Hoa Tran et al. Blood Adv 2018;2:529-533 © 2018 by The American Society of Hematology

Overall and event-free survival of NCI high-risk, Ph-negative, B-ALL patients by fusion and IKZF1 status. Overall and event-free survival of NCI high-risk, Ph-negative, B-ALL patients by fusion and IKZF1 status. (A-B) The 5-year OS and EFS for patients with Fusion+ patients were 68% (95% confidence interval [CI], 39% to 85%) and 48% (95% CI, 22% to 70%), respectively, in comparison with 88% (95% CI, 79% to 93%) and 78% (95% CI, 67% to 85%) for fusion-negative patients. (C-D) The 5-year OS and EFS for patients with IKZF1 deletion were 66% (95% CI, 45% to 81%) and 45% (95% CI, 25% to 62%), respectively, in comparison with 90% (95% CI, 79% to 95%) and 81% (95% CI, 69% to 89%) for patients without IKZF1 deletion. (E-F) The 5-year OS and EFS were 62% (95% CI, 28% to 84%) and 44% (95% CI, 15% to 70%), respectively, for patients with both fusion-positivity and IKZF1 deletion in comparison with 91% (95% CI, 79% to 96%) (P = .005) and 83% (95% CI, 71% to 90%) (P = .006) for those with neither. Del, deletion. Thai Hoa Tran et al. Blood Adv 2018;2:529-533 © 2018 by The American Society of Hematology